ArticleScientific reports2026
Association between the atherogenic index of plasma and cognitive impairment.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Atherogenic Index of Plasma (AIP), a burgeoning composite lipid marker that reflects overall lipid balance, has an incompletely understood longitudinal relationship with cognitive impairment. This study conducted a systematic investigation into the long-term, nonlinear association between AIP and the risk of cognitive impairment among middle-aged and older adults, utilizing longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS) spanning from 2011 to 2020. The study encompassed 2971 participants who were free from cognitive impairment at baseline and were followed for a period of up to 10 years. The cumulative incidence of new-onset cognitive impairment was found to be 40.46% in men and 54.45% in women. A multivariable-adjusted Cox regression analysis revealed that an elevated AIP, particularly within the 25th to 75th percentile range, was an independent risk factor for cognitive impairment (P < 0.05). Further analysis employing restricted cubic splines (RCS) uncovered a significant inverted U-shaped nonlinear association between AIP and cognitive impairment risk (P-nonlinear < 0.001), with a notably increased risk within the AIP range of 0.205 to 0.423. Subgroup analyses, stratified by sex, age, educational level, and BMI, showed consistent trends across various demographic groups. This study suggests that AIP, as a straightforward composite lipid marker, exhibits a significant nonlinear association with the risk of cognitive impairment in middle-aged and older adults. Monitoring AIP levels could assist in the early identification of individuals at high risk, and targeted interventions within specific AIP ranges, such as 0.205–0.423, could have significant public health implications, offering a new potential target for preventive strategies against cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.